Diagnosis of Pediatric Tumefactive Multiple Sclerosis with MRI Biomarkers
Neurol 107:e218575, Barter,K.M.,et al, 2026
Using Susceptibility-Based Imaging in Highly Active Late-Onset Multiple Sclerosis
Neurol 106:e214794, Sosa,S.M.,et al, 2026
Diagnostic Value of the Kappa Free light Chain Index to Distinguish MOGAD, NMOSD, and MS
Neurol 106:e214946, Tournier,A.,et al, 2026
Using Susceptibility-Based Imaging in highly ctive Late-Onset Multiple Sclerosis
Neurol 106:e214794, Sosa,S.M.,et al, 2026
Application of the 2024 McDonald Criteria in Individuals with Nonspecific Symptoms or Incidental Imaging Findings in a Multicenter Study
Neurol 107:e218138, e218210, Scharf,A.,et al, 2026
Application of the 2024 McDonald Criteria
Neurol 107:e218425, Solomon,A.J.,et al, 2026
Impact of 2024 Revisions of Multiple Sclerosis Diagnostic Criteria in People with Radiologically Isolated Syndrome
Neurol 107e218691, DiFilipppo,M.,et al, 2026
Frequency and Diagnostic Implications of Paramagnetic Rim Lesions in People Presenting for Diagnosis to a Multiple Sclerosis Clinic
Neurol 105:e213912, Remner,B.,et al, 2025
Diagnosis of Multiple Sclerosis: 2024 Revisions of the McDonald Criteria
Lancet Neurol 24:850-865, Montalban,X.,et al, 2025
Inhibition of CD40L with Frexalimab in Multiple Sclerosis
NEJM 390:589-600, 662, Vermersch,P.,et al, 2024
Kappa Free Light Chain Biomarkers are Efficient for the Diagnosis of Multiple Sclerosis
Neurol Neuroinflamm 10:e200049, Levraut,M.,et al, 2023
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Paramagnetic Rim Lesions are Specific to Multiple Sclerosis:An International Multicenter 3T MRI Study
Ann Neurol 88:1034-1042, Maggi,P.,et al, 2020
Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis
JAMA Neurol 76:1446-1456, Sinnecker, T.,et al, 2019
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Glial Fibrillary Acidic Protein Immunoglobulin G as Biomarker of Autoimmune Astrocytopathy: Analysis of 102 Patients
Ann Neurol 81:298-309, Flanagan, E.P.,et al, 2017
Comparing 3T and 1.5T MRI for Mapping Hippocampal Atrophy in the Alzheimers Disease Neuroimaging Initiative
AJNR 36:653-660, Chow, N.,et al, 2015
An Expanded Role for Neuroimaging in the Evaluation of Memory Impairment
AJNR 34:2075-2082, Desikan, R.S.,et al, 2013
Assessing Abnormal Iron Content in the Deep Gray Matter of Patients with Multiple Sclerosis verus Healthy Controls
AJNR 33:252258, Habib,C.A.,et al, 2012
Longitudinal Change of Biomakers in Cognitive Decline
Arch Neurol 68:1257-1266,1237, Lo, R.Y.,et al, 2011
Serial MRI and CSF Biomarkers in Normal Aging, MCI, and AD
Neurol 75:143-151, Vemuri,P., et al, 2010
Combining MR Imaging, Positron-Emission Tomography, and CSF Biomarkers in the Diagnosis and Prognosis of Alzheimers Disease
AJNR 31:347-354, Walhovd, K.B.,et al, 2010
Association of Plasma Leptin Levels With Incident Alzheimer Disease and MRI Measures of Brain Aging
JAMA 302:2565-2572, 2593, Lieb,W.,et al, 2009
Fully-Automated Quantification of Regional Brain Volumes for Improved Detection of Focal Atrophy in Alzheimers Disease
AJNR 30:578-580, Brewer, J.B.,et al, 2009
NMO-IgG Predicts the Outcome of Recurrent Optic Neuritis
Neurol 70:2197-2200, Matiello,M.,et al, 2008
TDP-43-Associated Neurodegenerative Disease Conceptualization and Integrated Staging, A Review
JAMA Neurol 83:1013-1022, Benatar,M.,et al, 2026
D-dimer >2.785 �g/ml and multiple infarcts =3 vascular territories are two characteristics of identifying cancer-associated ischemic stroke patients
Neurol Res 40:948-954, Wang, J.,et al, 2018
Predicting Alzheimer Disease with �-Amyloid Imaging: Results from the Australian Imaging, Biomarkers, and Lifestyle Study of Ageing
Ann Neurol 74:905-913, Rowe, C.C.,et al, 2013